Display options
Cite
Reiber R, Keller M, Keller W, et al. Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study. Clin Transl Allergy. 2016;6:9doi: 10.1186/s13601-016-0097-8.
Reiber, R., Keller, M., Keller, W., Wolf, H., Schnitker, J., & Wüstenberg, E. (2015). Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study. Clinical and translational allergy, 69. https://doi.org/10.1186/s13601-016-0097-8
Reiber, Rainer, et al. "Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study." Clinical and translational allergy vol. 6 (2015): 9. doi: https://doi.org/10.1186/s13601-016-0097-8
Reiber R, Keller M, Keller W, Wolf H, Schnitker J, Wüstenberg E. Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study. Clin Transl Allergy. 2016 Mar 08;6:9. doi: 10.1186/s13601-016-0097-8. eCollection 2015. PMID: 26958338; PMCID: PMC4782305.
Copy Download .nbib Format: NLM
Share it on

Clin Transl Allergy. 2016 Mar 08;6:9. doi: 10.1186/s13601-016-0097-8. eCollection 2015.

Tolerability of the SQ-standardised grass sublingual immunotherapy tablet in patients treated with concomitant allergy immunotherapy: a non-interventional observational study.

Clinical and translational allergy

Rainer Reiber, Martina Keller, Winfried Keller, Hendrik Wolf, Jörg Schnitker, Eike Wüstenberg

Affiliations

  1. HNO-Praxis, 73614 Schorndorf, Germany.
  2. HNO-Gemeinschaftspraxis, 78166 Donaueschingen, Germany.
  3. Clinical Development, ALK-Abelló Arzneimittel GmbH, 22763 Hamburg, Germany.
  4. Institut für angewandte Statistik Dr. Jörg Schnitker GmbH, 33602 Bielefeld, Germany.
  5. Medizin, ALK-Abelló Arzneimittel GmbH, 22763 Hamburg, Germany ; Clinic for Otolaryngology, Universitätsklinikum Carl Gustav Carus, 01307 Dresden, Germany.

PMID: 26958338 PMCID: PMC4782305 DOI: 10.1186/s13601-016-0097-8

Abstract

BACKGROUND: The majority of allergic patients are poly-sensitized. For causal treatment by allergy immunotherapy (AIT) a single or few allergen products containing the clinically most relevant allergens are applied, but few data on tolerability of multiple application of AIT is available. The aim of our study was to investigate safety and tolerability in patients who started treatment by sublingual immunotherapy (SLIT) with the standardised SQ(®) grass SLIT-tablet and were treated with concomitant AIT products.

METHODS: In a non-interventional, open-label, observational study in Germany treatment of patients with the SQ(®) grass SLIT-tablet and concomitant AIT (SCIT or SLIT) was documented between January 2012 and January 2014. Patients were followed at visits at first administration of the SQ(®) grass SLIT-tablet and after 1-3 months of treatment. Tolerability of the treatment with the SQ(®) grass SLIT-tablet and concomitant AIT were assessed by the physician and administration of AIT and adverse events (AEs) were recorded by the patients in diaries. AEs and adverse drug reactions (ADRs) were coded by using the Medical Dictionary for Regulatory Activities.

RESULTS: In total, 181 patients were documented by 48 allergists and 160 patients treated with a concomitant AIT (SCIT 130, SLIT 30). AEs were reported in 58 (36.3 %) patients with concomitant AIT, and AEs considered related with the SQ(®) grass SLIT-tablet in 49 (30.6 %) and with concomitant AIT in 18 (11.3 %) patients. Treatment was discontinued due to ADRs in 12 (7.5 %) patients and severity of ADRs was assessed mild or moderate in 29 (18.1 %), and severe in 20 (12.5 %) patients. Most common reactions were localised at the application site of the SQ(®) grass SLIT-tablet as oral pruritus, throat irritation, oedema mouth and paraesthesia oral; no serious ADRs were reported. Overall tolerability of the SQ(®) grass SLIT-tablet if given with concomitant AIT was assessed as "good" or "very good" by 91.0 % of patients and 91.6 % of physicians.

CONCLUSIONS: In comparison to data from previous studies no increase in frequency of AEs or change in the tolerability profile was observed when SLIT with the SQ(®) grass SLIT-tablet was administered with concomitant SCIT or SLIT.

Keywords: Allergic rhinoconjunctivitis; GRAZAX; Grass pollen; Multiple allergy immunotherapy; Polysensitization; Subcutaneous immunotherapy; Sublingual immunotherapy; Tolerability

References

  1. J Allergy Clin Immunol. 2011 Jan;127(1):64-71, 71.e1-4 - PubMed
  2. J Investig Allergol Clin Immunol. 2006;16(6):338-44 - PubMed
  3. J Allergy Clin Immunol. 2008 Feb;121(2):512-518.e2 - PubMed
  4. Pediatr Allergy Immunol. 2007 Sep;18(6):516-22 - PubMed
  5. Clin Drug Investig. 2013 Oct;33(10):719-26 - PubMed
  6. J Investig Allergol Clin Immunol. 2006;16(3):162-8 - PubMed
  7. J Allergy Clin Immunol. 2009 Jan;123(1):167-173.e7 - PubMed
  8. Allergy. 2006 Feb;61(2):185-90 - PubMed
  9. Ann Epidemiol. 2010 Nov;20(11):797-803 - PubMed
  10. Curr Opin Allergy Clin Immunol. 2014 Feb;14(1):20-4 - PubMed
  11. J Allergy Clin Immunol. 2010 Jan;125(1):131-8.e1-7 - PubMed
  12. Allergy. 2006 Feb;61(2):151-65 - PubMed
  13. World Allergy Organ J. 2015 May 14;8(1):17 - PubMed
  14. J Allergy Clin Immunol. 2011 Jan;127(1):72-80, 80.e1-2 - PubMed
  15. N Engl J Med. 1999 Aug 12;341(7):468-75 - PubMed
  16. Curr Pharm Biotechnol. 2001 Jun;2(2):175-86 - PubMed
  17. Allergy. 2015 Mar;70(3):302-9 - PubMed
  18. J Allergy Clin Immunol. 2012 Apr;129(4):929-34 - PubMed
  19. J Allergy Clin Immunol. 2012 Mar;129(3):717-725.e5 - PubMed
  20. Int Arch Allergy Immunol. 2005 Nov;138(3):197-202 - PubMed
  21. J Allergy Clin Immunol. 2006 Aug;118(2):434-40 - PubMed
  22. Med Etika Bioet. 2002 Spring-Summer;9(1-2):12-9 - PubMed
  23. Ann Allergy Asthma Immunol. 2014 Feb;112(2):146-153.e2 - PubMed
  24. Allergy. 2006 Oct;61(10):1209-15 - PubMed
  25. Chem Immunol Allergy. 2003;82:33-43 - PubMed
  26. Allergy. 2006 Feb;61(2):181-4 - PubMed
  27. Eur Arch Otorhinolaryngol. 2010 Dec;267(12):1873-9 - PubMed
  28. J Allergy Clin Immunol. 2006 Apr;117(4):802-9 - PubMed
  29. Allergy. 2008 Dec;63(12):1637-9 - PubMed

Publication Types